fashion -WSS

fashion

author：entertainment 2025-10-01 23:39:26 - browse：4997

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： In 'major milestone,' FDA approves first cell therapy for solid tumors

WSS

Measles policy set amid Florida outbreak alarms vaccine proponents

Reporting on presidential health from Reagan to Trump and Biden

Senate committee scrutinizes Medicare Advantage brokers

Flagship Pioneering startup Sonata Therapeutics lays off 21

Medicare reduced heart disease by changing how it pays doctors

Elevance, SCAN deals highlight health insurer acquisition scrutiny

focus

fashion

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ukraine seeks to reclaim its role as a hub for clinical trials

Psychedelics group wrestles with new pharma identity

Pharmacists can make shortage drugs, but at what cost?

Sports medicine is finally prioritizing gender equality

FDA gives detailed accounting of AI

Novavax promises a turnaround & Lilly roils the obesity market

Researchers explore possible ties between long Covid, menopause

Anesthesiologist group: stop taking Ozempic before surgery

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

WATCH: Why do our ears pop?

2023 STAT Wunderkinds: get to know the winners

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

First Opinion Podcast: Long Covid needs a new approach

Studies point to risks of excluding people with obesity from drug trials

Wikipedia

entertainment

hotspot

knowledge